Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

The publication will be followed by an investor conference call and webcast on Tuesday, Nov Cellectis SA (CLLS ... gene insertion methods. These developments could significantly enhance therapeutic ...

Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, ...

The attack came just days after President Biden gave Ukraine permission to use the weapons to strike targets inside Russia. By Marc Santora and Eric Schmitt The envoy, Amos Hochstein, said an ...

Stewart-Haas' sad demise belies its legacy of unlikely success (October 31, 2024, 7:00 PM ET) ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...